OCGN Company Profile and Key Details

Ocugen, Inc. (NASDAQ:OCGN) closed at $1.40 USD, losing -$0.08 (-5.41%) from the previous close of $1.48. The stock is currently mid-range between its 52-week high and low $0.52 and $1.90. With a market capitalization of about $437.25 million, Ocugen, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~4.54). Key stats such as the average daily volume over the past year has been around 4.73 million shares, volume is running light vs its 52-week average. Headquartered in Malvern, PA, Ocugen, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Shankar Musunuri, the company employs approximately 95 people and listed since December 03, 2014. Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases.

Short-term trend indicators are mixed aligned (SMA20 15.26%, SMA50 7.97%, SMA200 37.74%). The stock’s 14-day RSI is 63.05 (firm momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -22.11% below its high and over 187.38% above its low. Average 10-day trading volume of 5.20 million shares is in line with the 3-month average of 4.79 million, indicating normal recent market interest.

Ocugen, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.03. This means the shares are trading above this model’s fair value.

Ocugen, Inc. has 312.30 million shares outstanding. The public float is 287.94 million shares, elevated short interest at 19.04% of float. This equals 54.76 million shares. The short ratio is 13.59 days. Institutional investors hold 16.89% of the float. Insiders own 1.49%. Musunuri Shankar holds 2.19 million shares, KIRK RANDAL J has 1.69 million shares and Zhang Junge has 1.08 million shares.

Ocugen, Inc. generated EPS of -$0.22 over the past year. Five-year average earnings growth is 32.82%. Wall Street analysts project EPS growth of 44.07% annually over the next five years. The latest quarter delivered EPS of -$0.07. The next quarter is forecast at -$0.06. Next year's EPS is expected at $3.42. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $8.00 to $6.00. The high target offers 440.54% upside. The low target suggests 305.41% downside. The mean target is $7.00. This offers 372.97% upside. Ocugen, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by 14.71%. The prior quarter beat by -16.67%. Over the last six quarters, Apple has recorded several small beats. These include -1.05% in August 08, 2024.

Ocugen, Inc. (NASDAQ:OCGN) shares are up 83.85% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ocugen, Inc. trading at a premium to the broader market with a P/E of -7.23. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.00, suggesting 305.41% upside. Our AI forecast model points to short-term strength (17.57% over two weeks), a medium-term fall (-2.03% over three months), and a longer-term gain (1464.19% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Ocugen, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 17.57%, with price expected at $1.74 by January 05, 2026, within a range of $1.67 to $1.81 3-Month Outlook: Projected fall of -2.03%, reaching $1.45 by March 20, 2026, with a range of $1.21 to $1.62. 1-Year Outlook: Projected gain of 1464.19%, with price at $23.15 by December 22, 2026, within a range of $24.11 to $24.39.

Ocugen, Inc. trades at a P/E ratio of -7.23, slightly below the S&P 500 average, with a price-to-sales ratio of 92.63 and a price-to-book ratio of 134.92 reflecting a rich premium to book value. The P/FCF stands at -8.42, also below market averages. Compared to sector medians, Ocugen, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.